We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+13.18%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$25B
AUM Growth
+$2.35B
Cap. Flow
+$638M
Cap. Flow %
2.55%
Top 10 Hldgs %
85.68%
Holding
126
New
11
Increased
17
Reduced
63
Closed
6

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$358M
2
PRLD icon
Prelude Therapeutics
PRLD
+$286M
3
KYMR icon
Kymera Therapeutics
KYMR
+$59.8M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$55.5M
5
NRIX icon
Nurix Therapeutics
NRIX
+$45.1M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$94.5M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$26.6M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$21.6M
4
INSM icon
Insmed
INSM
+$21.6M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.35%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
101
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$1.76M 0.01%
12,412
-660
-5% -$110K
BLCM
102
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.64M 0.01%
249,123
– –
MTEM
103
DELISTED
Molecular Templates, Inc.
MTEM
$1.63M 0.01%
9,921
-627
-6% -$111K
OYST
104
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$1.44M 0.01%
68,228
-3,200
-4% -$74.8K
ORTX
105
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.41M 0.01%
34,320
-6,250
-15% -$323K
CPRX
106
DELISTED
Catalyst Pharmaceutical
CPRX
$1.41M 0.01%
474,400
-25,600
-5% -$100K
GTH
107
DELISTED
Genetron Holdings Limited ADS
GTH
$1.19M ﹤0.01%
+33,333
New +$1.28M
CYPH
108
Cypherpunk Technologies Inc
CYPH
$63.1M
$1.11M ﹤0.01%
55,971
-41,874
-43% -$808K
EVFM
109
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$1.02M ﹤0.01%
28,870
-66,130
-70% -$2.87M
APLT
110
DELISTED
Applied Therapeutics
APLT
$790K ﹤0.01%
38,034
-27,900
-42% -$725K
GLMD icon
111
Galmed Pharmaceuticals
GLMD
$4.42M
$725K ﹤0.01%
1,141
-57
-5% -$46.5K
INFI
112
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$679K ﹤0.01%
580,400
– –
ADMS
113
DELISTED
Adamas Pharmaceuticals
ADMS
$675K ﹤0.01%
163,830
-8,800
-5% -$34K
AFMD
114
DELISTED
Affimed
AFMD
$643K ﹤0.01%
18,980
-1,020
-5% -$38.6K
ARAV
115
DELISTED
Aravive, Inc. Common Stock
ARAV
$357K ﹤0.01%
75,854
-168,201
-69% -$1.19M
GNFT
116
DELISTED
Genfit
GNFT
$150K ﹤0.01%
28,396
– –
VIRX
117
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$66K ﹤0.01%
15,162
-743
-5% -$6.49K
ABEO icon
118
Abeona Therapeutics
ABEO
$342M
– –
-63,627
Closed -$4.64M
MRKR icon
119
Marker Therapeutics
MRKR
$19.3M
– –
-24,051
Closed -$498K
MTNB icon
120
Matinas BioPharma
MTNB
$1.83M
– –
-41,928
Closed -$1.62M
TCDA
121
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-787,582
Closed -$21.6M
AIMT
122
DELISTED
Aimmune Therapeutics
AIMT
– –
-673,908
Closed -$11.3M
PRNB
123
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
– –
-1,580,873
Closed -$94.5M
1 2 3 4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2020 Portfolio in Review

As of Q3 2020, Baker Bros. Advisors held 126 positions worth $25B, up 10% from $22.7B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q3 2020 filing shows 11 new, 17 increased, 63 reduced and 6 closed positions. Its largest new stake was Prelude Therapeutics: 10,118,636 shares worth $305M. The largest sale was Principia Biopharma Inc. Common Stock, an estimated $94.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q3 2020 buy was Prelude Therapeutics: 10,118,636 shares worth $305M.
  • Baker Bros. Advisors added most to BeOne Medicines Ltd in Q3 2020, an estimated $358M increase.
  • Baker Bros. Advisors's biggest Q3 2020 reduction was Neurocrine Biosciences, cutting an estimated $26.6M.
  • Baker Bros. Advisors fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $94.5M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $25B portfolio in Q3 2020.
  • Baker Bros. Advisors opened 11 new positions and closed 6 in Q3 2020.
  • Baker Bros. Advisors's portfolio value rose 10% quarter-over-quarter to $25B.

Based on Baker Bros. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.